Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?

Breast Cancer Res. 2012 Nov 13;14(6):115. doi: 10.1186/bcr3332.


A recent prospective clinical trial provides further evidence that breast cancers arising in germline BRCA1 mutation carriers are highly sensitive to cisplatin chemotherapy. The potential significance of these data for the management of patients with BRCA1-related and BRCA2-related breast cancer is discussed.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics*
  • Cisplatin / therapeutic use*
  • Female
  • Genes, BRCA1*
  • Humans


  • Antineoplastic Agents
  • Cisplatin